financetom
Business
financetom
/
Business
/
Tata Power completes sale of its defence biz to Tata Advanced Systems
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Tata Power completes sale of its defence biz to Tata Advanced Systems
Nov 2, 2020 4:39 AM

Tata Power on Monday said it has completed the sale of its defence business to Tata Advanced Systems. Tata Advanced Systems is a wholly-owned subsidiary of Tata Sons. ”The sale was completed as per a Scheme of Arrangement, which was approved by the National Company Law Tribunal at Mumbai and Hyderabad in December 2019 and March 2020, respectively,” Tata Power said in a regulatory filing. The company said it is expected to receive an enterprise value of Rs 1,076 crore as an upfront payment.

Balance consideration is subject to completion of achieving certain milestones specified in the agreements, the company added. Tata Power said the sale of defence business is part of the company’s ongoing strategic plan to monetise its non-core assets and reduce overall leverage.

”The sale proceeds will help the company to reduce leverage and increase focus in the core business areas like renewable generation, distribution and new service-led businesses which will bring greater value for our shareholders,” Praveer Sinha, CEO and Managing Director, Tata Power said. Strategic Engineering Division (SED) is a non-core defence electronics division of the company, engaged in business of indigenous design, development, production, integration, supply and life cycle support of mission-critical defence systems.

The key products include manufacturing and assembling missile launchers, electronic warfare, night vision systems and gun systems. SED has three dedicated manufacturing units — Bangalore Electronic City, Vemagal in Karnataka (under construction) and an SEZ near Bengaluru (under construction).

First Published:Nov 2, 2020 1:39 PM IST

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Anaergia's Italian Unit Expands Scope at Three Biomethane Facilities Being Built in Italy, Increasing Contracts by C$17 Million
Anaergia's Italian Unit Expands Scope at Three Biomethane Facilities Being Built in Italy, Increasing Contracts by C$17 Million
Mar 17, 2026
06:33 AM EDT, 03/17/2026 (MT Newswires) -- An Italian subsidiary of Anaergia ( ANRGF ) signed amendments to three previously announced contracts with an entity owned by QGM relating to the development of three state-of-the-art biomethane production facilities in Ostellato, Copparo, and Derovere, in northern Italy, the company said on Tuesday. The company further said that, as a result of...
Nvidia bets on AI inference as chip revenue opportunity hits $1 trillion
Nvidia bets on AI inference as chip revenue opportunity hits $1 trillion
Mar 17, 2026
SAN JOSE, California, March 16 (Reuters) - Nvidia ( NVDA ) said the revenue opportunity for its artificial intelligence chips may reach at least $1 trillion through 2027, as the company outlined a strategy to compete more aggressively in the fast-growing market for running AI systems in real time. CEO Jensen Huang unveiled a new central processor and an AI...
Roche ramps up AI computing capacity with Nvidia chip expansion
Roche ramps up AI computing capacity with Nvidia chip expansion
Mar 17, 2026
BERLIN, March 16 (Reuters) - Swiss drugmaker Roche said on Monday it had expanded its artificial intelligence computing capacity with more than 2,100 Nvidia ( NVDA ) chips to support drug and diagnostics development. Roche said the additional hardware would speed up work across its research and development operations, including modelling, data analysis and clinical trial processes. The drugmaker said...
Greenwich LifeSciences Says Breast Cancer Therapy Reduces Cancer Recurrence in Late-Stage Study
Greenwich LifeSciences Says Breast Cancer Therapy Reduces Cancer Recurrence in Late-Stage Study
Mar 17, 2026
06:37 AM EDT, 03/17/2026 (MT Newswires) -- Greenwich LifeSciences ( GLSI ) said Tuesday that preliminary data from its late-stage trial of its experimental therapy, GLSI-100, to prevent breast cancer recurrences, showed a continued reduction in recurrence rates among certain patients. The drug developer said six months of additional patient data demonstrated recurrence rate of less than 1% per year...
Copyright 2023-2026 - www.financetom.com All Rights Reserved